CTOs on the Move

Tarcine

www.tarcine.com

 
Tarcine is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tarcine.com
  • 1560 Newbury Rd 161
    Thousand Oaks, CA USA 91320
  • Phone: 805.558.7037

Executives

Name Title Contact Details

Similar Companies

Annexon Biosciences

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.

University Technologies International

University Technologies International is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Midwest AgEnergy Group

Midwest AgEnergy Group is a North Dakota biofuels enterprise. Midwest AgEnergy Group owns Blue Flint Ethanol, a 65 million gallon per year biorefinery in operation since 2007 near Underwood, N.D., and Dakota Spirit AgEnergy, a 65 million gallon per year biorefinery east of Jamestown, ND that began production in June 2015. Together with our partners, we are building a renewable energy future for the country, increasing demand for North Dakota farmers, and bringing prosperity to our communities.

9 Meters

9 Meters Biopharma is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS), larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease, and several near clinical-stage assets.

Treasure Coast Radiation Oncology, Pa

Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.